Comorbidity in Multiple Sclerosis
Comorbidities in patients with multiple sclerosis (MS) has become an area of increasing interest in the recent years. A comorbidity is defined as any additional disease that coexists in an individual with a given index disease and that is not an obvious complication of the index disease. The aim of...
Saved in:
| Published in: | Frontiers in neurology Vol. 11; p. 851 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Frontiers Media S.A
21.08.2020
|
| Subjects: | |
| ISSN: | 1664-2295, 1664-2295 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Comorbidities in patients with multiple sclerosis (MS) has become an area of increasing interest in the recent years. A comorbidity is defined as any additional disease that coexists in an individual with a given index disease and that is not an obvious complication of the index disease. The aim of this review is to describe the current evidence regarding the range of comorbidities in the population with MS reported in different countries and the current knowledge about the influence of comorbidities on the clinical features and therapeutic challenges in MS. Certain comorbidities are more prevalent in people with MS such as depression, anxiety, cerebro- and cardiovascular diseases, and certain autoimmune disorders such as diabetes, thyroid disease, and inflammatory bowel disease. A previous perception of a trend toward a lower overall risk of cancer in patients with MS appears to be challenged, but there is no evidence on any higher occurrence of malignancies in the population with MS. Comorbidities may modify the clinical presentation of MS, and have implications for treatment choice, adherence, and outcome. Several comorbid conditions are associated with increased disability progression, including diabetes, hypertension, and chronic obstructive pulmonary disease. Comorbidities are common in MS from the time of diagnosis and may account for some of the heterogeneity observed in MS, including diagnostic delay, clinical presentation, degree of disability progression, rate of health care utilization, working ability, employment status, and quality of life. Coexisting diseases and polypharmacy increase the complexity of patient management and poses major challenges, particularly with the increasing number of immunosuppressive disease-modifying therapies.Comorbidities in patients with multiple sclerosis (MS) has become an area of increasing interest in the recent years. A comorbidity is defined as any additional disease that coexists in an individual with a given index disease and that is not an obvious complication of the index disease. The aim of this review is to describe the current evidence regarding the range of comorbidities in the population with MS reported in different countries and the current knowledge about the influence of comorbidities on the clinical features and therapeutic challenges in MS. Certain comorbidities are more prevalent in people with MS such as depression, anxiety, cerebro- and cardiovascular diseases, and certain autoimmune disorders such as diabetes, thyroid disease, and inflammatory bowel disease. A previous perception of a trend toward a lower overall risk of cancer in patients with MS appears to be challenged, but there is no evidence on any higher occurrence of malignancies in the population with MS. Comorbidities may modify the clinical presentation of MS, and have implications for treatment choice, adherence, and outcome. Several comorbid conditions are associated with increased disability progression, including diabetes, hypertension, and chronic obstructive pulmonary disease. Comorbidities are common in MS from the time of diagnosis and may account for some of the heterogeneity observed in MS, including diagnostic delay, clinical presentation, degree of disability progression, rate of health care utilization, working ability, employment status, and quality of life. Coexisting diseases and polypharmacy increase the complexity of patient management and poses major challenges, particularly with the increasing number of immunosuppressive disease-modifying therapies. |
|---|---|
| AbstractList | Comorbidities in patients with multiple sclerosis (MS) has become an area of increasing interest in the recent years. A comorbidity is defined as any additional disease that coexists in an individual with a given index disease and that is not an obvious complication of the index disease. The aim of this review is to describe the current evidence regarding the range of comorbidities in the population with MS reported in different countries and the current knowledge about the influence of comorbidities on the clinical features and therapeutic challenges in MS. Certain comorbidities are more prevalent in people with MS such as depression, anxiety, cerebro- and cardiovascular diseases, and certain autoimmune disorders such as diabetes, thyroid disease, and inflammatory bowel disease. A previous perception of a trend toward a lower overall risk of cancer in patients with MS appears to be challenged, but there is no evidence on any higher occurrence of malignancies in the population with MS. Comorbidities may modify the clinical presentation of MS, and have implications for treatment choice, adherence, and outcome. Several comorbid conditions are associated with increased disability progression, including diabetes, hypertension, and chronic obstructive pulmonary disease. Comorbidities are common in MS from the time of diagnosis and may account for some of the heterogeneity observed in MS, including diagnostic delay, clinical presentation, degree of disability progression, rate of health care utilization, working ability, employment status, and quality of life. Coexisting diseases and polypharmacy increase the complexity of patient management and poses major challenges, particularly with the increasing number of immunosuppressive disease-modifying therapies. Comorbidities in patients with multiple sclerosis (MS) has become an area of increasing interest in the recent years. A comorbidity is defined as any additional disease that coexists in an individual with a given index disease and that is not an obvious complication of the index disease. The aim of this review is to describe the current evidence regarding the range of comorbidities in the population with MS reported in different countries and the current knowledge about the influence of comorbidities on the clinical features and therapeutic challenges in MS. Certain comorbidities are more prevalent in people with MS such as depression, anxiety, cerebro- and cardiovascular diseases, and certain autoimmune disorders such as diabetes, thyroid disease, and inflammatory bowel disease. A previous perception of a trend toward a lower overall risk of cancer in patients with MS appears to be challenged, but there is no evidence on any higher occurrence of malignancies in the population with MS. Comorbidities may modify the clinical presentation of MS, and have implications for treatment choice, adherence, and outcome. Several comorbid conditions are associated with increased disability progression, including diabetes, hypertension, and chronic obstructive pulmonary disease. Comorbidities are common in MS from the time of diagnosis and may account for some of the heterogeneity observed in MS, including diagnostic delay, clinical presentation, degree of disability progression, rate of health care utilization, working ability, employment status, and quality of life. Coexisting diseases and polypharmacy increase the complexity of patient management and poses major challenges, particularly with the increasing number of immunosuppressive disease-modifying therapies.Comorbidities in patients with multiple sclerosis (MS) has become an area of increasing interest in the recent years. A comorbidity is defined as any additional disease that coexists in an individual with a given index disease and that is not an obvious complication of the index disease. The aim of this review is to describe the current evidence regarding the range of comorbidities in the population with MS reported in different countries and the current knowledge about the influence of comorbidities on the clinical features and therapeutic challenges in MS. Certain comorbidities are more prevalent in people with MS such as depression, anxiety, cerebro- and cardiovascular diseases, and certain autoimmune disorders such as diabetes, thyroid disease, and inflammatory bowel disease. A previous perception of a trend toward a lower overall risk of cancer in patients with MS appears to be challenged, but there is no evidence on any higher occurrence of malignancies in the population with MS. Comorbidities may modify the clinical presentation of MS, and have implications for treatment choice, adherence, and outcome. Several comorbid conditions are associated with increased disability progression, including diabetes, hypertension, and chronic obstructive pulmonary disease. Comorbidities are common in MS from the time of diagnosis and may account for some of the heterogeneity observed in MS, including diagnostic delay, clinical presentation, degree of disability progression, rate of health care utilization, working ability, employment status, and quality of life. Coexisting diseases and polypharmacy increase the complexity of patient management and poses major challenges, particularly with the increasing number of immunosuppressive disease-modifying therapies. |
| Author | Magyari, Melinda Sorensen, Per Soelberg |
| AuthorAffiliation | 2 Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital , Rigshospitalet , Denmark 1 Department of Neurology, Danish Multiple Sclerosis Center, Copenhagen University Hospital, Rigshospitalet , Denmark |
| AuthorAffiliation_xml | – name: 1 Department of Neurology, Danish Multiple Sclerosis Center, Copenhagen University Hospital, Rigshospitalet , Denmark – name: 2 Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital , Rigshospitalet , Denmark |
| Author_xml | – sequence: 1 givenname: Melinda surname: Magyari fullname: Magyari, Melinda – sequence: 2 givenname: Per Soelberg surname: Sorensen fullname: Sorensen, Per Soelberg |
| BookMark | eNp1kc1vGyEQxVGVqnZd33N0brnYHRgW2EukyMqHpVQ9tD0jWFiXaL04sBsp_32wHVVNpXIBDe_9ZjTvMznrY-8JOaewQlT117b3Y1oxYLACUBX9QKZUCL5krK7O_npPyDznRygH6xoFfiITZLVEUfEpuVjHXUw2uDC8LEK_-DZ2Q9h3fvGj6XyKOeQv5GNruuznb_eM_Lq9-bm-Xz58v9usrx-WDcd6WFbSoeFobcW9NVRSpoCDlEo45pT1KNExhao1RlpHQRSpMx6ordq2Ei3OyObEddE86n0KO5NedDRBHwsxbbVJQyhjacqaFrwyyjDDrZelpwQQtROcKcVZYV2dWPvR7rxrfD8k072Dvv_pw2-9jc9acokIvAAu3wApPo0-D3oXcuO7zvQ-jlkzzoUQlQAsUjhJm7KunHz7pw0FfQhKH4PSh6D0MahiEf9YmjCYIcTDMKH7v_EVfnyY0A |
| CitedBy_id | crossref_primary_10_3390_jcm14020324 crossref_primary_10_1080_13548506_2024_2411634 crossref_primary_10_1016_j_msard_2023_104693 crossref_primary_10_3389_fneur_2022_844873 crossref_primary_10_1007_s11011_024_01347_2 crossref_primary_10_3390_ijms22052498 crossref_primary_10_1016_j_jns_2024_123156 crossref_primary_10_1007_s00415_025_13173_2 crossref_primary_10_36469_jheor_2022_38669 crossref_primary_10_1186_s42466_025_00379_y crossref_primary_10_1016_j_msard_2020_102705 crossref_primary_10_1111_ene_16586 crossref_primary_10_1177_20552173251352735 crossref_primary_10_5937_respira2502170T crossref_primary_10_1055_a_2283_7401 crossref_primary_10_3389_fneur_2023_1128315 crossref_primary_10_1016_j_jocn_2022_11_008 crossref_primary_10_1177_13524585211066598 crossref_primary_10_3389_fneur_2025_1521112 crossref_primary_10_1007_s12035_024_04458_0 crossref_primary_10_1016_j_dhjo_2022_101344 crossref_primary_10_1177_15598276221141403 crossref_primary_10_1016_j_msard_2024_106228 crossref_primary_10_1016_j_msard_2023_105398 crossref_primary_10_7224_1537_2073_2023_103 crossref_primary_10_1016_j_msard_2023_104903 crossref_primary_10_1080_00207454_2024_2327404 crossref_primary_10_1016_j_jns_2024_123161 crossref_primary_10_3390_brainsci15090944 crossref_primary_10_1097_NRL_0000000000000632 crossref_primary_10_1093_humrep_deac041 crossref_primary_10_12998_wjcc_v10_i21_7415 crossref_primary_10_1177_13524585241245653 crossref_primary_10_3390_brainsci14111141 crossref_primary_10_1007_s13668_024_00538_8 crossref_primary_10_3389_fimmu_2024_1379538 crossref_primary_10_3390_jcm10215207 crossref_primary_10_1007_s12325_025_03252_1 crossref_primary_10_4103_ijpvm_ijpvm_5_23 crossref_primary_10_1016_S1634_7072_23_48431_0 crossref_primary_10_3390_ijms24098251 crossref_primary_10_1016_j_farma_2023_05_005 crossref_primary_10_3389_fimmu_2021_669811 crossref_primary_10_3390_ijerph19042203 crossref_primary_10_3897_pharmacia_71_e117681 crossref_primary_10_1097_MD_0000000000039709 crossref_primary_10_1111_ene_15551 crossref_primary_10_7759_cureus_75226 crossref_primary_10_3390_ijms22147377 crossref_primary_10_3390_jpm13111524 crossref_primary_10_7224_1537_2073_2022_046 crossref_primary_10_3389_fimmu_2023_1196999 crossref_primary_10_1177_20552173231186516 crossref_primary_10_1016_j_jns_2025_123409 crossref_primary_10_1177_17562864241279118 crossref_primary_10_1186_s12974_023_02696_y crossref_primary_10_3390_healthcare11172420 crossref_primary_10_1002_acn3_70155 crossref_primary_10_1155_2024_7549306 crossref_primary_10_1096_fj_202201348R crossref_primary_10_1016_j_genrep_2022_101599 crossref_primary_10_1111_ene_70019 crossref_primary_10_3390_ijerph21101264 crossref_primary_10_3390_jcm14124304 crossref_primary_10_1111_ane_13559 crossref_primary_10_1177_13524585211031791 crossref_primary_10_1177_13524585231223880 crossref_primary_10_1186_s12883_021_02347_w crossref_primary_10_1016_j_farma_2024_02_015 crossref_primary_10_7224_1537_2073_2022_051 crossref_primary_10_1016_j_ejpn_2025_04_001 crossref_primary_10_3389_fneur_2024_1444470 crossref_primary_10_1097_PHM_0000000000002312 crossref_primary_10_1080_00207454_2022_2056459 crossref_primary_10_1177_17562864241229325 crossref_primary_10_1007_s00281_021_00907_3 crossref_primary_10_1016_j_msard_2025_106556 crossref_primary_10_1016_j_msard_2025_106677 crossref_primary_10_1007_s43440_023_00469_1 crossref_primary_10_1016_j_msard_2023_104936 crossref_primary_10_1177_13524585221075542 crossref_primary_10_3389_fneur_2023_1286122 crossref_primary_10_4103_aam_aam_49_24 crossref_primary_10_36469_001c_38669 crossref_primary_10_1007_s00415_023_12041_1 crossref_primary_10_7759_cureus_68565 crossref_primary_10_1007_s40273_021_01035_4 crossref_primary_10_1177_20552173231198588 crossref_primary_10_1016_j_bbih_2024_100787 crossref_primary_10_1080_1744666X_2021_1986005 crossref_primary_10_1177_20552173251315458 crossref_primary_10_1080_09638288_2025_2552871 crossref_primary_10_31083_j_jin2101033 crossref_primary_10_3389_fneur_2022_863105 crossref_primary_10_1016_j_msard_2024_105455 crossref_primary_10_1038_s41398_023_02555_7 crossref_primary_10_2147_IJWH_S334719 crossref_primary_10_3390_brainsci13050708 crossref_primary_10_3390_vaccines11020410 crossref_primary_10_3389_fimmu_2022_991291 crossref_primary_10_7224_1537_2073_2022_113 crossref_primary_10_1136_jnnp_2021_326839 crossref_primary_10_1016_j_apmr_2023_06_019 crossref_primary_10_2217_pmt_2021_0001 crossref_primary_10_1136_bmjopen_2024_088808 crossref_primary_10_1007_s10198_022_01547_6 crossref_primary_10_3390_jcm14113689 crossref_primary_10_1017_cjn_2024_288 crossref_primary_10_1016_j_autrev_2023_103358 crossref_primary_10_1016_j_farma_2024_05_002 crossref_primary_10_1016_j_msard_2025_106613 crossref_primary_10_3390_jpm14040400 crossref_primary_10_1016_j_msard_2025_106456 crossref_primary_10_3390_jpm12111828 crossref_primary_10_3389_fimmu_2024_1469614 crossref_primary_10_1002_hsr2_2247 crossref_primary_10_1249_JES_0000000000000291 crossref_primary_10_1016_j_msard_2021_102813 crossref_primary_10_1134_S2079057024600630 crossref_primary_10_3389_fneur_2021_719088 crossref_primary_10_3389_fphar_2022_946351 crossref_primary_10_1016_j_celrep_2025_116326 crossref_primary_10_1371_journal_pone_0311117 crossref_primary_10_1002_jclp_23483 crossref_primary_10_1186_s12888_021_03633_0 crossref_primary_10_1016_j_ebiom_2025_105559 crossref_primary_10_3390_geriatrics7030061 crossref_primary_10_1159_000544813 crossref_primary_10_1016_j_smrv_2023_101842 crossref_primary_10_1111_ene_70214 crossref_primary_10_1177_1357633X20964693 crossref_primary_10_1038_s41598_024_61876_9 crossref_primary_10_1016_j_vaccine_2023_01_003 crossref_primary_10_3389_fcell_2021_752350 crossref_primary_10_1007_s00115_021_01155_4 |
| Cites_doi | 10.1177/1352458518791753 10.1212/WNL.0000000000002474 10.1016/j.msard.2019.08.005 10.1371/journal.pone.0045295 10.1016/0021-9681(87)90171-8 10.1212/WNL.0000000000004716 10.1177/1352458512437814 10.1186/s12883-019-1366-7 10.1007/s00415-018-8949-x 10.1186/s13104-017-2958-1 10.1136/jnnp-2017-315907 10.1212/WNL.0000000000001187 10.1111/ene.13297 10.1016/S0895-4356(02)00585-1 10.1136/bmjopen-2015-007806 10.1177/1352458514540970 10.1111/ane.13132 10.1007/s00415-018-8811-1 10.1093/qjmed/95.11.753 10.1016/j.msard.2018.08.022 10.1177/1352458519877244 10.1016/j.msard.2019.02.014 10.1007/s11910-019-0992-1 10.1177/1352458514521515 10.1212/wnl.0000000000004686 10.1177/1352458514564487 10.7224/1537-2073.2016-110 10.2147/prom.s148387 10.1159/000442203 10.1111/ene.12518 10.1016/j.msard.2018.10.109 10.1093/clipsy/6.1.1 10.1007/s11910-015-0546-0 10.1111/ene.12710 10.1097/phm.0000000000000563 10.7224/1537-2073.2016-015 10.1016/j.msard.2016.10.003 10.1016/j.jns.2016.10.040 10.1016/j.msard.2018.03.008 10.1212/01.wnl.0000333252.78173.5f 10.1007/s40263-018-0564-y 10.1177/1352458514564485 10.1016/j.jclinepi.2010.10.006 10.7224/1537-2073.2014-084 10.1177/1352458515588973 10.1001/jamaneurol.2020.0664 10.1038/nrneurol.2014.139 10.1038/s41582-019-0183-3 10.1016/j.jns.2016.09.005 10.1186/1471-2377-14-117 10.1177/1352458514564489 10.1016/j.msard.2018.12.012 10.1212/WNL.0000000000004508 10.1007/s00415-012-6790-1 10.1056/nejmoa1610528 10.1212/WNL.0000000000002471 10.1159/000311013 10.1371/journal.pone.0148573 10.1002/14651858.CD010968 10.1016/j.msard.2017.10.019 10.1212/cpj.0000000000000230 10.1177/1352458511417835 10.1177/1352458514564491 10.1007/s00415-016-8340-8 10.1136/jnnp-2019-322369 10.1111/ane.12916 10.1177/1352458516650512 10.1016/S0895-4356(03)00246-4 10.1016/j.sleep.2019.01.010 10.1212/WNL.0b013e3181d6b125 10.1016/j.msard.2016.05.009 10.1007/s00415-016-8295-9 10.1212/WNL.0000000000002564 10.3174/ajnr.A4681 10.1016/j.jns.2014.11.019 10.1212/WNL.0000000000004411 10.2337/dc13-1414 10.1016/j.msard.2017.11.003 10.1016/j.smrv.2016.03.004 10.1159/000320245 10.1212/WNL.0000000000005302 10.1038/nrneurol.2017.33 10.1212/WNL.0000000000008617 10.1007/s11910-018-0809-7 10.1177/1352458514564488 10.1016/j.msard.2018.12.015 10.1186/s12883-017-0932-0 10.1002/ana.25701 10.1177/1352458511414041 10.1212/WNL.0000000000004037 10.1016/j.msard.2018.12.014 10.1212/CPJ.0000000000000269 10.1016/0021-9681(70)90054-8 10.1111/ene.14040 10.1016/j.cca.2015.01.035 10.1001/archneur.63.7.1001 10.1016/j.smrv.2014.10.002 10.1212/WNL.0000000000002543 10.1016/j.msard.2016.10.008 10.1159/000488799 |
| ContentType | Journal Article |
| Copyright | Copyright © 2020 Magyari and Sorensen. Copyright © 2020 Magyari and Sorensen. 2020 Magyari and Sorensen |
| Copyright_xml | – notice: Copyright © 2020 Magyari and Sorensen. – notice: Copyright © 2020 Magyari and Sorensen. 2020 Magyari and Sorensen |
| DBID | AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.3389/fneur.2020.00851 |
| DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1664-2295 |
| ExternalDocumentID | oai_doaj_org_article_12cf0e8a8a2a4be7b5470069d6428842 PMC7473304 10_3389_fneur_2020_00851 |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK E3Z EMOBN F5P GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 P2P PGMZT RNS RPM 7X8 5PM |
| ID | FETCH-LOGICAL-c439t-57d3a43bb54eba171280407786d2d8be373d2838faa7bd1063bbdae01b5ff56f3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 146 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000568263300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1664-2295 |
| IngestDate | Fri Oct 03 12:29:23 EDT 2025 Thu Aug 21 13:41:35 EDT 2025 Thu Oct 02 06:32:31 EDT 2025 Sat Nov 29 05:08:21 EST 2025 Tue Nov 18 20:51:03 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c439t-57d3a43bb54eba171280407786d2d8be373d2838faa7bd1063bbdae01b5ff56f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Neurology Reviewed by: Elisabeth Gulowsen Celius, Department of Neurology, Oslo University Hospital, Norway; Emanuele D'amico, University of Catania, Italy Edited by: Bruno Stankoff, Sorbonne Universités, France |
| OpenAccessLink | https://doaj.org/article/12cf0e8a8a2a4be7b5470069d6428842 |
| PMID | 32973654 |
| PQID | 2446665603 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_12cf0e8a8a2a4be7b5470069d6428842 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7473304 proquest_miscellaneous_2446665603 crossref_primary_10_3389_fneur_2020_00851 crossref_citationtrail_10_3389_fneur_2020_00851 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-08-21 |
| PublicationDateYYYYMMDD | 2020-08-21 |
| PublicationDate_xml | – month: 08 year: 2020 text: 2020-08-21 day: 21 |
| PublicationDecade | 2020 |
| PublicationTitle | Frontiers in neurology |
| PublicationYear | 2020 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Frau (B70) 2017; 89 Gaindh (B33) 2016; 370 Marrie (B75) 2011; 17 Kowalec (B54) 2017; 89 Bechtold (B22) 2014; 37 Rossi (B50) 2017; 89 Zhang (B69) 2016; 86 Nørgaard (B35) 2019; 28 Kallweit (B62) 2018; 265 Sieminski (B61) 2015; 22 Pakpoor (B53) 2012; 7 Gross (B25) 2011 Raissi (B51) 2015; 17 Simpson (B47) 2019; 30 Thormann (B4) 2017; 24 Feinstein (B81) 2011; 17 Blizzard (B76) 2016; 46 Benchimol (B8) 2011; 64 Marrie (B15) 2016; 6 Montgomery (B40) 2015; 22 Marrie (B44) 2017; 10 Thormann (B67) 2017; 89 Ewanchuk (B97) 2018; 26 Horton (B9) 2010; 35 Dobson (B23) 2013; 260 Lebrun (B34) 2018; 32 Hoang (B45) 2016; 22 Marrie (B12) 2015; 21 Fakolade (B99) 2016; 18 Palladino (B17) 2020; 77 Lorefice (B92) 2018; 265 Tremlett (B27) 2002; 95 Ragonese (B36) 2017; 17 Marrie (B100) 2016; 86 Marrie (B55) 2016; 8 Vandenabeele (B96) 2016; 96 Hughes (B63) 2018; 18 Conway (B71) 2017; 23 Marrie (B32) 2015; 21 Edwards (B43) 2018; 9 Feinstein (B1) 1970; 23 Vaughn (B93) 2019; 15 Hill (B30) 2019; 28 Pham (B49) 2018; 19 Geraldes (B95) 2020; 91 Marrie (B82) 2015; 84 Gascoyne (B48) 2019; 140 Kosmidou (B26) 2017; 264 McKay (B83) 2018; 51 Marck (B10) 2016; 11 Marrie (B41) 2015; 21 McKay (B72) 2018; 90 Gentile (B66) 2015; 449 Chou (B89) 2020; 27 Zhang (B24) 2017; 11 Kalb (B90) 2019; 19 Hongell (B37) 2019; 35 Butler (B91) 2016; 10 Johansson (B46) 2014; 20 Marrie (B3) 2015; 21 Nociti (B59) 2017; 372 Feinstein (B42) 2014; 10 De Jong (B101) 2017; 88 Zivadinov (B78) 2016; 37 Luczynski (B64) 2019; 27 Marrie (B74) 2010; 74 Koch-Henriksen (B5) 2017; 88 Thormann (B14) 2016; 263 Roshanisefat (B16) 2014; 21 Tinghög (B84) 2014; 14 Magyari (B21) 2014; 20 Murtonen (B86) 2018; 19 Grytten (B38) 2019 Maschio (B77) 2017; 376 Foschi (B56) 2019; 56 Hong (B18) 2019; 19 Alping (B39) 2020; 87 Binzer (B73) 2019; 93 Bang Oturai (B2) 2018; 25 Popp (B58) 2017; 32 Abdel Salam (B60) 2019; 28 Marrie (B31) 2015; 21 Salter (B87) 2016; 6 Thormann (B28) 2016; 10 Heydarpour (B98) 2018; 138 Marrie (B13) 2012; 18 Marrie (B79) 2018; 20 Berrigan (B80) 2016; 86 Marrie (B94) 2017; 13 Christiansen (B85) 2010; 35 de Groot (B6) 2003; 56 Marrie (B11) 2016; 86 Charlson (B88) 1987; 40 Manouchehrinia (B29) 2015; 5 Wilchesky (B7) 2004; 57 Marrie (B68) 2009; 72 Veauthier (B57) 2015; 15 Roy (B65) 2018; 22 Tettey (B19) 2015; 348 Mohr (B52) 1999; 6 Study (B20) 2013; 63 |
| References_xml | – volume: 25 start-page: 1298 year: 2018 ident: B2 article-title: Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis publication-title: Mult Scler J. doi: 10.1177/1352458518791753 – volume: 86 start-page: 1446 year: 2016 ident: B11 article-title: Recommendations for observational studies of comorbidity in multiple sclerosis publication-title: Neurology. doi: 10.1212/WNL.0000000000002474 – volume: 35 start-page: 221 year: 2019 ident: B37 article-title: Risk of cancer among Finnish multiple sclerosis patients publication-title: Mult Scler Relat Disord. doi: 10.1016/j.msard.2019.08.005 – volume: 7 start-page: e45295 year: 2012 ident: B53 article-title: Meta-analysis of the relationship between multiple sclerosis and migraine publication-title: PLoS ONE. doi: 10.1371/journal.pone.0045295 – volume: 40 start-page: 373 year: 1987 ident: B88 article-title: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation publication-title: J Chronic Dis. doi: 10.1016/0021-9681(87)90171-8 – volume: 89 start-page: 2455 year: 2017 ident: B54 article-title: Comorbidity increases the risk of relapse in multiple sclerosis publication-title: Neurology. doi: 10.1212/WNL.0000000000004716 – volume: 18 start-page: 1310 year: 2012 ident: B13 article-title: Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia publication-title: Mult Scler J. doi: 10.1177/1352458512437814 – volume: 19 start-page: 1 year: 2019 ident: B18 article-title: Multiple sclerosis and stroke: a systematic review and meta-analysis publication-title: BMC Neurol. doi: 10.1186/s12883-019-1366-7 – volume: 265 start-page: 2071 year: 2018 ident: B62 article-title: Coexisting narcolepsy (with and without cataplexy) and multiple sclerosis: six new cases and a literature review publication-title: J Neurol. doi: 10.1007/s00415-018-8949-x – volume: 10 start-page: 1 year: 2017 ident: B44 article-title: Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data publication-title: BMC Res Notes. doi: 10.1186/s13104-017-2958-1 – volume: 88 start-page: 626 year: 2017 ident: B5 article-title: Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp-2017-315907 – volume: 84 start-page: 350 year: 2015 ident: B82 article-title: Comorbidity increases the risk of hospitalizations in multiple sclerosis publication-title: Neurology. doi: 10.1212/WNL.0000000000001187 – volume: 24 start-page: 825 year: 2017 ident: B4 article-title: Chronic comorbidity in multiple sclerosis is associated with lower incomes and dissolved intimate relationships publication-title: Eur J Neurol. doi: 10.1111/ene.13297 – volume: 56 start-page: 221 year: 2003 ident: B6 article-title: How to measure comorbidity. a critical review of available methods publication-title: J Clin Epidemiol. doi: 10.1016/S0895-4356(02)00585-1 – volume: 5 start-page: e007806 year: 2015 ident: B29 article-title: Multiple sclerosis course and clinical outcomes in patients with comorbid asthma: a survey study publication-title: BMJ Open. doi: 10.1136/bmjopen-2015-007806 – volume: 20 start-page: 1881 year: 2014 ident: B46 article-title: Multiple sclerosis and psychiatric disorders: comorbidity and sibling risk in a nationwide Swedish cohort publication-title: Mult Scler J. doi: 10.1177/1352458514540970 – volume: 140 start-page: 204 year: 2019 ident: B48 article-title: Modifiable factors associated with depression and anxiety in multiple sclerosis publication-title: Acta Neurol Scand. doi: 10.1111/ane.13132 – volume: 265 start-page: 1096 year: 2018 ident: B92 article-title: Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A case–control MRI study publication-title: J Neurol. doi: 10.1007/s00415-018-8811-1 – volume: 95 start-page: 753 year: 2002 ident: B27 article-title: Asthma and multiple sclerosis: an inverse association in a case-control general practice population publication-title: QJM. doi: 10.1093/qjmed/95.11.753 – volume: 26 start-page: 19 year: 2018 ident: B97 article-title: Exploring the role of physical activity and exercise for managing vascular comorbidities in people with multiple sclerosis: a scoping review publication-title: Mult Scler Relat Disord. doi: 10.1016/j.msard.2018.08.022 – year: 2019 ident: B38 article-title: Risk of cancer among multiple sclerosis patients, siblings, and population controls: a prospective cohort study publication-title: Mult Scler J. doi: 10.1177/1352458519877244 – volume: 30 start-page: 165 year: 2019 ident: B47 article-title: Associations of demographic and clinical factors with depression over 2.5-years in an international prospective cohort of people living with MS publication-title: Mult Scler Relat Disord. doi: 10.1016/j.msard.2019.02.014 – volume: 19 start-page: 4 year: 2019 ident: B90 article-title: Depression and suicidality in multiple sclerosis: red flags, management strategies, and ethical considerations publication-title: Curr Neurol Neurosci Rep. doi: 10.1007/s11910-019-0992-1 – volume: 20 start-page: 1244 year: 2014 ident: B21 article-title: Gender and autoimmune comorbidity in multiple sclerosis publication-title: Mult Scler J. doi: 10.1177/1352458514521515 – volume: 89 start-page: 2222 year: 2017 ident: B70 article-title: Assessing association of comorbidities with treatment choice and persistence in MS publication-title: Neurology. doi: 10.1212/wnl.0000000000004686 – volume: 21 start-page: 305 year: 2015 ident: B41 article-title: The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review publication-title: Mult Scler J. doi: 10.1177/1352458514564487 – volume: 20 start-page: 76 year: 2018 ident: B79 article-title: Diagnoses of depression and anxiety versus current symptoms and quality of life in multiple sclerosis publication-title: Int J MS Care. doi: 10.7224/1537-2073.2016-110 – volume: 9 start-page: 97 year: 2018 ident: B43 article-title: Comorbidity in US patients with multiple sclerosis publication-title: Patient Relat Outcome Meas. doi: 10.2147/prom.s148387 – volume: 46 start-page: 106 year: 2016 ident: B76 article-title: Frequency of comorbidities and their association with clinical disability and relapse in multiple sclerosis publication-title: Neuroepidemiology. doi: 10.1159/000442203 – volume: 21 start-page: 1353 year: 2014 ident: B16 article-title: Multiple sclerosis clinical course and cardiovascular disease risk—Swedish cohort study publication-title: Eur J Neurol. doi: 10.1111/ene.12518 – volume: 27 start-page: 232 year: 2019 ident: B64 article-title: Coexistence of multiple sclerosis and Alzheimer's disease: a review publication-title: Mult Scler Relat Disord. doi: 10.1016/j.msard.2018.10.109 – volume: 6 start-page: 1 year: 1999 ident: B52 article-title: Treatment of depression in multiple sclerosis: review and meta-analysis publication-title: Clin Psychol Sci Pract. doi: 10.1093/clipsy/6.1.1 – volume: 15 start-page: 1 year: 2015 ident: B57 article-title: Sleep disorders in multiple sclerosis. Review publication-title: Curr Neurol Neurosci Rep. doi: 10.1007/s11910-015-0546-0 – volume: 22 start-page: 1074 year: 2015 ident: B40 article-title: All-cause mortality following a cancer diagnosis amongst multiple sclerosis patients: a Swedish population-based cohort study publication-title: Eur J Neurol. doi: 10.1111/ene.12710 – volume: 96 start-page: 161 year: 2016 ident: B96 article-title: High intensity aerobic and resistance exercise can improve glucose tolerance in persons with multiple sclerosis publication-title: Am J Phys Med Rehabil. doi: 10.1097/phm.0000000000000563 – volume: 18 start-page: 282 year: 2016 ident: B99 article-title: Effect of comorbidities on outcomes of neurorehabilitation interventions in multiple sclerosis: a scoping review publication-title: Int J MS Care. doi: 10.7224/1537-2073.2016-015 – volume: 10 start-page: 145 year: 2016 ident: B91 article-title: A systematic review of anxiety amongst people with Multiple Sclerosis publication-title: Mult Scler Relat Disord. doi: 10.1016/j.msard.2016.10.003 – volume: 372 start-page: 387 year: 2017 ident: B59 article-title: Sleep and fatigue in multiple sclerosis: a questionnaire-based, cross-sectional, cohort study publication-title: J Neurol Sci. doi: 10.1016/j.jns.2016.10.040 – volume: 22 start-page: 52 year: 2018 ident: B65 article-title: Preliminary investigation of cognitive function in aged multiple sclerosis patients: challenges in detecting comorbid Alzheimer's disease publication-title: Mult Scler Relat Disord. doi: 10.1016/j.msard.2018.03.008 – volume: 72 start-page: 117 year: 2009 ident: B68 article-title: Comorbidity delays diagnosis and increases disability at diagnosis in MS publication-title: Neurology. doi: 10.1212/01.wnl.0000333252.78173.5f – volume: 32 start-page: 939 year: 2018 ident: B34 article-title: Cancer risk in patients with multiple sclerosis: potential impact of disease-modifying drugs publication-title: CNS Drugs. doi: 10.1007/s40263-018-0564-y – volume: 21 start-page: 318 year: 2015 ident: B12 article-title: A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis publication-title: Mult Scler J. doi: 10.1177/1352458514564485 – volume: 64 start-page: 821 year: 2011 ident: B8 article-title: Development and use of reporting guidelines for assessing the quality of validation studies of health administrative data publication-title: J Clin Epidemiol. doi: 10.1016/j.jclinepi.2010.10.006 – volume: 17 start-page: 292 year: 2015 ident: B51 article-title: Exploration of undertreatment and patterns of treatment of depression in multiple sclerosis publication-title: Int J MS Care. doi: 10.7224/1537-2073.2014-084 – volume: 22 start-page: 347 year: 2016 ident: B45 article-title: Psychiatric co-morbidity in multiple sclerosis: the risk of depression and anxiety before and after MS diagnosis publication-title: Mult Scler J. doi: 10.1177/1352458515588973 – volume: 77 start-page: 1 year: 2020 ident: B17 article-title: Evaluating the risk of macrovascular events and mortality among people with multiple sclerosis in England publication-title: JAMA Neurol. doi: 10.1001/jamaneurol.2020.0664 – volume: 10 start-page: 507 year: 2014 ident: B42 article-title: The link between multiple sclerosis and depression publication-title: Nat Rev Neurol. doi: 10.1038/nrneurol.2014.139 – volume: 15 start-page: 329 year: 2019 ident: B93 article-title: Epidemiology and treatment of multiple sclerosis in elderly populations publication-title: Nat Rev Neurol. doi: 10.1038/s41582-019-0183-3 – volume: 370 start-page: 13 year: 2016 ident: B33 article-title: Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk publication-title: J Neurol Sci. doi: 10.1016/j.jns.2016.09.005 – volume: 14 start-page: 1 year: 2014 ident: B84 article-title: Co-morbidities increase the risk of disability pension among MS patients: a population-based nationwide cohort study publication-title: BMC Neurol. doi: 10.1186/1471-2377-14-117 – volume: 21 start-page: 294 year: 2015 ident: B32 article-title: A systematic review of the incidence and prevalence of cancer in multiple sclerosis publication-title: Mult Scler J. doi: 10.1177/1352458514564489 – volume: 28 start-page: 69 year: 2019 ident: B30 article-title: Prevalence of asthma in multiple sclerosis: a United States population-based study publication-title: Mult Scler Relat Disord. doi: 10.1016/j.msard.2018.12.012 – volume: 89 start-page: 4508 year: 2017 ident: B67 article-title: Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality publication-title: Neurology. doi: 10.1212/WNL.0000000000004508 – volume: 260 start-page: 1272 year: 2013 ident: B23 article-title: Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis publication-title: J Neurol. doi: 10.1007/s00415-012-6790-1 – volume: 376 start-page: 1615 year: 2017 ident: B77 article-title: Overexpression of the cytokine BAFF and autoimmunity risk publication-title: N Engl J Med. doi: 10.1056/nejmoa1610528 – volume: 86 start-page: 1437 year: 2016 ident: B100 article-title: The challenge of comorbidity in clinical trials for multiple sclerosis publication-title: Neurology. doi: 10.1212/WNL.0000000000002471 – volume: 35 start-page: 83 year: 2010 ident: B9 article-title: Validation of a self-report comorbidity questionnaire for multiple sclerosis publication-title: Neuroepidemiology. doi: 10.1159/000311013 – volume: 11 start-page: 1 year: 2016 ident: B10 article-title: Prevalence of comorbidities, overweight and obesity in an international sample of people with multiple sclerosis and associations with modifiable lifestyle factors publication-title: PLoS ONE. doi: 10.1371/journal.pone.0148573 – volume: 11 start-page: CD010968 year: 2017 ident: B24 article-title: Alemtuzumab versus interferon beta 1a for relapsing- remitting multiple sclerosis publication-title: Review doi: 10.1002/14651858.CD010968 – volume: 19 start-page: 109 year: 2018 ident: B86 article-title: Common comorbidities and survival in MS: risk for stroke, type 1 diabetes and infections publication-title: Mult Scler Relat Disord. doi: 10.1016/j.msard.2017.10.019 – volume: 6 start-page: 120 year: 2016 ident: B15 article-title: Differing trends in the incidence of vascular comorbidity in MS and the general population publication-title: Neurol Clin Pract. doi: 10.1212/cpj.0000000000000230 – volume: 17 start-page: 1276 year: 2011 ident: B81 article-title: Multiple sclerosis and depression publication-title: Mult Scler J. doi: 10.1177/1352458511417835 – volume: 21 start-page: 263 year: 2015 ident: B3 article-title: A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview publication-title: Mult Scler J. doi: 10.1177/1352458514564491 – volume: 264 start-page: 254 year: 2017 ident: B26 article-title: Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis publication-title: J Neurol. doi: 10.1007/s00415-016-8340-8 – volume: 91 start-page: 388 year: 2020 ident: B95 article-title: Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis publication-title: J Neurol Neurosurg Psychiatry. doi: 10.1136/jnnp-2019-322369 – volume: 138 start-page: 62 year: 2018 ident: B98 article-title: Smoking and worsening disability in multiple sclerosis: a meta-analysis publication-title: Acta Neurol Scand. doi: 10.1111/ane.12916 – volume: 23 start-page: 277 year: 2017 ident: B71 article-title: Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course publication-title: Mult Scler. doi: 10.1177/1352458516650512 – volume: 57 start-page: 131 year: 2004 ident: B7 article-title: Validation of diagnostic codes within medical services claims publication-title: J Clin Epidemiol. doi: 10.1016/S0895-4356(03)00246-4 – volume: 56 start-page: 90 year: 2019 ident: B56 article-title: Sleep-related disorders and their relationship with MRI findings in multiple sclerosis publication-title: Sleep Med. doi: 10.1016/j.sleep.2019.01.010 – volume: 74 start-page: 1041 year: 2010 ident: B74 article-title: Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis publication-title: Neurology doi: 10.1212/WNL.0b013e3181d6b125 – volume: 8 start-page: 86 year: 2016 ident: B55 article-title: Chronic lung disease and multiple sclerosis: incidence, prevalence, and temporal trends publication-title: Mult Scler Relat Disord. doi: 10.1016/j.msard.2016.05.009 – volume: 263 start-page: 9 year: 2016 ident: B14 article-title: Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark publication-title: J Neurol. doi: 10.1007/s00415-016-8295-9 – volume: 86 start-page: 1417 year: 2016 ident: B80 article-title: Health-related quality of life in multiple sclerosis publication-title: Neurology. doi: 10.1212/WNL.0000000000002564 – volume: 37 start-page: 1010 year: 2016 ident: B78 article-title: Autoimmune comorbidities are associated with brain injury in multiple sclerosis publication-title: Am J Neuroradiol. doi: 10.3174/ajnr.A4681 – volume: 348 start-page: 126 year: 2015 ident: B19 article-title: The co-occurrence of multiple sclerosis and type 1 diabetes: shared aetiologic features and clinical implication for MS aetiology publication-title: J Neurol Sci. doi: 10.1016/j.jns.2014.11.019 – volume: 89 start-page: 1338 year: 2017 ident: B50 article-title: Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis publication-title: Neurology. doi: 10.1212/WNL.0000000000004411 – volume: 37 start-page: 96 year: 2014 ident: B22 article-title: Higher relative risk for multiple sclerosis in a pediatric and adolescent diabetic population: analysis from dpv database publication-title: Diabetes Care. doi: 10.2337/dc13-1414 – volume: 19 start-page: 35 year: 2018 ident: B49 article-title: The prevalence of anxiety and associated factors in persons with multiple sclerosis publication-title: Mult Scler Relat Disord. doi: 10.1016/j.msard.2017.11.003 – volume: 32 start-page: 95 year: 2017 ident: B58 article-title: Daytime sleepiness versus fatigue in patients with multiple sclerosis: a systematic review on the Epworth sleepiness scale as an assessment tool publication-title: Sleep Med Rev. doi: 10.1016/j.smrv.2016.03.004 – volume: 35 start-page: 267 year: 2010 ident: B85 article-title: Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study publication-title: Neuroepidemiology. doi: 10.1159/000320245 – volume: 90 start-page: e1316 year: 2018 ident: B72 article-title: Psychiatric comorbidity is associated with disability progression in multiple sclerosis publication-title: Neurology. doi: 10.1212/WNL.0000000000005302 – volume: 13 start-page: 375 year: 2017 ident: B94 article-title: Comorbidity in multiple sclerosis: implications for patient care publication-title: Nat Rev Neurol. doi: 10.1038/nrneurol.2017.33 – volume: 93 start-page: E2216 year: 2019 ident: B73 article-title: Disability worsening among persons with multiple sclerosis and depression: a Swedish cohort study publication-title: Neurology. doi: 10.1212/WNL.0000000000008617 – volume: 18 start-page: 7 year: 2018 ident: B63 article-title: Sleep disturbance and cognitive dysfunction in multiple sclerosis: a systematic review publication-title: Curr Neurol Neurosci Rep. doi: 10.1007/s11910-018-0809-7 – volume: 21 start-page: 332 year: 2015 ident: B31 article-title: The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: a systematic review publication-title: Mult Scler J. doi: 10.1177/1352458514564488 – volume: 28 start-page: 184 year: 2019 ident: B60 article-title: Risk of obstructive sleep apnea in multiple sclerosis: frequency, clinical and radiological correlates publication-title: Mult Scler Relat Disord. doi: 10.1016/j.msard.2018.12.015 – volume: 17 start-page: 155 year: 2017 ident: B36 article-title: Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study publication-title: BMC Neurol. doi: 10.1186/s12883-017-0932-0 – volume: 87 start-page: 688 year: 2020 ident: B39 article-title: Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients publication-title: Ann Neurol. doi: 10.1002/ana.25701 – volume: 17 start-page: 1464 year: 2011 ident: B75 article-title: Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis publication-title: Mult Scler J. doi: 10.1177/1352458511414041 – volume: 88 start-page: 2310 year: 2017 ident: B101 article-title: Evaluating the safety of β-interferons in MS publication-title: Neurology. doi: 10.1212/WNL.0000000000004037 – volume: 28 start-page: 81 year: 2019 ident: B35 article-title: Multiple sclerosis and cancer incidence: a Danish nationwide cohort study publication-title: Mult Scler Relat Disord. doi: 10.1016/j.msard.2018.12.014 – volume: 6 start-page: 397 year: 2016 ident: B87 article-title: Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS publication-title: Neurol Clin Pract. doi: 10.1212/CPJ.0000000000000269 – start-page: 191 year: 2011 ident: B25 article-title: Interferon β in multiple sclerosis: a review. In: Translational Neuroimmunology in Multiple Sclerosis: From Disease Mechanisms to Clinical Applications – volume: 23 start-page: 455 year: 1970 ident: B1 article-title: The pre-therapeutic classification of comorbidity in chronic disease publication-title: J Chron Dis. doi: 10.1016/0021-9681(70)90054-8 – volume: 27 start-page: 105 year: 2020 ident: B89 article-title: Comorbidity in multiple sclerosis: its temporal relationships with disease onset and dose effect on mortality publication-title: Eur J Neurol. doi: 10.1111/ene.14040 – volume: 449 start-page: 23 year: 2015 ident: B66 article-title: Role of amyloid-β CSF levels in cognitive deficit in MS publication-title: Clin Chim Acta. doi: 10.1016/j.cca.2015.01.035 – volume: 63 start-page: 12 year: 2013 ident: B20 article-title: Type 1 diabetes and multiple sclerosis publication-title: Arch Neurol. doi: 10.1001/archneur.63.7.1001 – volume: 22 start-page: 15 year: 2015 ident: B61 article-title: Restless legs syndrome in multiple sclerosis publication-title: Sleep Med Rev. doi: 10.1016/j.smrv.2014.10.002 – volume: 86 start-page: 1287 year: 2016 ident: B69 article-title: Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis publication-title: Neurology. doi: 10.1212/WNL.0000000000002543 – volume: 10 start-page: 8 year: 2016 ident: B28 article-title: Inverse comorbidity in multiple sclerosis: findings in a complete nationwide cohort publication-title: Mult Scler Relat Disord. doi: 10.1016/j.msard.2016.10.008 – volume: 51 start-page: 1 year: 2018 ident: B83 article-title: Comorbidities are associated with altered health services use in multiple sclerosis: a prospective cohort study publication-title: Neuroepidemiology. doi: 10.1159/000488799 |
| SSID | ssj0000399363 |
| Score | 2.5652308 |
| SecondaryResourceType | review_article |
| Snippet | Comorbidities in patients with multiple sclerosis (MS) has become an area of increasing interest in the recent years. A comorbidity is defined as any... |
| SourceID | doaj pubmedcentral proquest crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | 851 |
| SubjectTerms | coexisting diseases comorbidities comorbidity [MeSH] multiple sclerosis Neurology registry |
| Title | Comorbidity in Multiple Sclerosis |
| URI | https://www.proquest.com/docview/2446665603 https://pubmed.ncbi.nlm.nih.gov/PMC7473304 https://doaj.org/article/12cf0e8a8a2a4be7b5470069d6428842 |
| Volume | 11 |
| WOSCitedRecordID | wos000568263300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: Directory of Open Access Journals customDbUrl: eissn: 1664-2295 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399363 issn: 1664-2295 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1664-2295 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000399363 issn: 1664-2295 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEB5URLyIT1xfdMGLh7Jt05rkqKJ4cBfBB3sLSZNgQbqyu3r0tzuTVtle9OKlh3ZKkm-SzEwyfANwijY_cUy6WJqExbksi1hqU8Zcam9NjhY0VJ57vuOjkRiP5f1CqS_KCWvogRvgBmlW-sQJLXSmc-O4KXJO9LqWHGeRh9034XIhmAp7MNndc9bcS2IUJgee-CExHswolUsUaccOBbr-jo_ZzZBcMDk3m7DR-orRRdPHLVhy9TasDdvb8B3o42KeTE1l0ZOOqjoatsmB0QOKY6vVbBeebq4fr27jtuRBXKJnMI8LbpnOmcFROqNTjtYDVxlxvNnMCuMYZxYdAuG15sZiOIeiVrskNYX3xblne7BST2q3D5FBT8BJblzqGcZgpbAyS1AjTrKcG-F7MPgGQJUtHziVpXhVGBcQZCpApggyFSDrwdnPH28NF8YvspeE6Y8csViHF6hb1epW_aXbHvS_NaJw1tNVhq7d5H2mMrqGJt4g1gPeUVWnxe6XunoJ_NkYQdEpzsF_dPEQ1mnQdMqcpUewMp--u2NYLT_m1Wx6Ast8LE7C1MTn8PP6C6Ou6I0 |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comorbidity+in+Multiple+Sclerosis&rft.jtitle=Frontiers+in+neurology&rft.au=Magyari%2C+Melinda&rft.au=Sorensen%2C+Per+Soelberg&rft.date=2020-08-21&rft.pub=Frontiers+Media+S.A&rft.eissn=1664-2295&rft.volume=11&rft_id=info:doi/10.3389%2Ffneur.2020.00851&rft_id=info%3Apmid%2F32973654&rft.externalDocID=PMC7473304 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-2295&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-2295&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-2295&client=summon |